The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 10, 2018

Filed:

Dec. 07, 2012
Applicant:

Duke University, Durham, NC (US);

Inventors:

Sally Kornbluth, Durham, NC (US);

Manabu Kurokawa, Durham, NC (US);

Neil Spector, Durham, NC (US);

Mark Dewhirst, Durham, NC (US);

Assignee:

Duke University, Durham, NC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); G01N 33/50 (2006.01); A61K 39/395 (2006.01); C07K 16/32 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 31/496 (2006.01); A61K 31/404 (2006.01); A61K 31/407 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 31/404 (2013.01); A61K 31/407 (2013.01); A61K 31/496 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/32 (2013.01); C12N 15/1135 (2013.01); C12N 15/1137 (2013.01); C12Y 603/02 (2013.01); G01N 33/5011 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.


Find Patent Forward Citations

Loading…